BPR1J-340

WARNING: This product is for research use only, not for human or veterinary use.

Description:BPR1J-340 is a potent and selective FLT3 inhibitor with potential anticancer activity. BPR1J-340 was identified as a novel potent FLT3 inhibitor by biochemical kinase activity (IC50 approximately 25 nM) and cellular proliferation (GC50 approximately 5 nM) assays. BPR1J-340 inhibited the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD(+) AML cells. The pharmacokinetic parameters of BPR1J-340 in rats were determined. BPR1J-340 also demonstrated pronounced tumor growth inhibition and regression in FLT3-ITD(+) AML murine xenograft models. The combination treatment of the HDAC inhibitor vorinostat (SAHA) with BPR1J-340 synergistically induced apoptosis via Mcl-1 down-regulation in MOLM-13 AML cells, indicating that the combination of selective FLT3 kinase inhibitors and HDAC inhibitors could exhibit clinical benefit in AML therapy.

Price and Availability

BPR1J-340,is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 406488Name: BPR1J-340CAS#: 1395051-72-5Chemical Formula: C29H34N8O3Exact Mass: 542.27539Molecular Weight: 542.63206Elemental Analysis: C, 64.19; H, 6.32; N, 20.65; O, 8.85

Synonym:BPR1J340; BPR1J 340; BPR1J-340.

IUPAC/Chemical Name:N-(3-(4-((3-(5-ethylisoxazol-3-yl)ureido)methyl)phenyl)-1H-pyrazol-5-yl)-4-((4-methylpiperazin-1-yl)methyl)benzamide

InChi Key:VHFDRDHFZFLAAT-UHFFFAOYSA-N

InChi Code:InChI=1S/C29H34N8O3/c1-3-24-16-27(35-40-24)32-29(39)30-18-20-4-8-22(9-5-20)25-17-26(34-33-25)31-28(38)23-10-6-21(7-11-23)19-37-14-12-36(2)13-15-37/h4-11,16-17H,3,12-15,18-19H2,1-2H3,(H2,30,32,35,39)(H2,31,33,34,38)

SMILES Code:O=C(NC1=CC(C2=CC=C(CNC(NC3=NOC(CC)=C3)=O)C=C2)=NN1)C4=CC=C(CN5CCN(C)CC5)C=C4

Technical Data

Additional Information

References

1: Lin WH, Yeh TK, Jiaang WT, Yen KJ, Chen CH, HuangCT, Yen SC, Hsieh SY, Chou LH, Chen CP, Chiu CH, Kao LC, Chao YS, Chen CT, Hsu JT. Evaluation ofthe antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor,alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer. PLoSOne. 2014Jan 8;9(1):e83160. doi: 10.1371/journal.pone.0083160. eCollection 2014.PubMed PMID: 24416160; PubMed Central PMCID: PMC3885398